Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1528-1536

  Marinovich, M L ^a   Macaskill, P ^a   Irwig, L ^a   Sardanelli, F ^b   Von Minckwitz, G ^c   Mamounas, E ^d   Brennan, M ^a   Ciatto, S ^e   Houssami, N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d M D ANDERSON CANCER CENTER ORLANDO   (United States)

^e APSS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SIZE; CANCER STAGING; CLINICAL EXAMINATION; EMBASE; HISTOPATHOLOGY; HUMAN; MAMMOGRAPHY; MASTECTOMY; MEASUREMENT ERROR; MEDLINE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; TUMOR BURDEN;

EID: 84884591817     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.473     Document Type: Article

References (46)

1. Akazawa K, Tamaki Y, Taguchi T, Tanji Y, Miyoshi Y, Kim SJ, Ueda S, Yanagisawa T, Sato Y, Tamura S, Noguchi S (2006) Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 12(2): 130-137.
2. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R (2002) Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Res Treat 72(2): 145-152.
3. Behjatnia B, Sim J, Bassett LW, Moatamed NA, Apple SK (2010) Does size matter? Comparison study between MRI, gross, and microscopic tumor sizes in breast cancer in lumpectomy specimens. Int J Clin Exp Pathol 3(3): 303-309.
4. Belli P, Costantini M, Malaspina C, Magistrelli A, LaTorre G, Bonomo L (2006) MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 61(11): 946-953.
5. Berg WA, Madsen KS, Schilling K, Tartar M, Pisano ED, Larsen LH, Narayanan D, Ozonoff A, Miller JP, Kalinyak JE (2010) Breast cancer: Comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology 258(1): 59-72.
6. Bhattacharyya M, Ryan D, Carpenter R, Vinnicombe S, Gallagher CJ (2008) Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer 98(2): 289-293.
7. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 327(8476): 307-310.
8. Bland JM, Altman DG (1990) A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement. Comput Biol Med 20(5): 337-340.
9. Bodini M, Berruti A, Bottini A, Allevi G, Fiorentino C, Brizzi MP, Bersiga A, Generali D, Volpi D, Marini U, Aguggini S, Tampellini M, Alquati P, Olivetti L, Dogliotti L (2004) Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Res Treat 85(3): 211-218.
10. Bollet MA, Thibault F, Bouillon K, Meunier M, Sigal-Zafrani B, Savignoni A, Dieras V, Nos C, Salmon R, Fourquet A (2007) Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: A prospective phase II study. Int J Radiat Oncol Biol Phys 69(1): 13-18.
11. Bossuyt PM, Leeflang MM (2008) Developing Criteria For Including Studies. In Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. The Cochrane Collaboration. Available at http://srdta.cochrane.org/sites/srdta.cochrane.org/files/uploads/Chapter06-Including-Studies%20%28 September-2008%29.pdf.
12. Chen X, Moore MO, Lehman CD, Mankoff DA, Lawton TJ, Peacock S, Schubert EK, Livingston RB (2004) Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 11(10): 1115-1124.
13. Cheung YC, Chen SC, Su MY, See LC, Hsueh S, Chang HK, Lin YC, Tsai CS (2003) Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Res Treat 78(1): 51-58.
14. Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G, Brunereau L (2004) Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 30(10): 1069-1076.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247.
16. Glasziou P, Irwig L, Deeks JJ (2008) When should a new test become the current reference standard? Ann Intern Med 149(11): 816-821.
17. Guarneri V, Pecchi A, Piacentini F, Barbieri E, Dieci MV, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Conte P, Torricelli P (2011) Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. Ann Surg Oncol 18(8): 2150-2157.
18. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327(7414): 557-560.
19. Irwig L, Bennetts A (1997) Quality of life after breast conservation or mastectomy: A systematic review. Aust New Zealand J Surg 67(11): 750-754.
20. Julius T, Kemp SEG, Kneeshaw PJ, Chaturvedi A, Drew PJ, Turnbull LW (2005) MRI and conservative treatment of locally advanced breast cancer. Eur J Surg Oncol 31(10): 1129-1134.
21. Lagios MD (2005) Problems in the assessment of tumor size: An elusive grail in current practice. Semin Breast Dis 8(1): 24-30.
22. Lobbes M, Prevos R, Smidt M (2012) Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using breast MRI-a review of current knowledge. Cancer Ther Res 1(34): Doi:10.7243/2049-7962-1-34.
23. Lobbes MBI, Prevos R, Smidt M, Tjan-Heijnen VCG, Goethem M, Schipper R, Beets-Tan RG, Wildberger JE (2013) The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: A systematic review. Insights Imaging 4: 163-175.
24. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C (2004) Locally advanced breast cancer: Comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14(8): 1371-1379.
25. Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, Von Minckwitz G, Brennan ME, Ciatto S (2013) Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 105(5): 321-333.
26. Marinovich ML, Sardanelli F, Ciatto S, Mamounas E, Brennan M, Macaskill P, Irwig L, Von Minckwitz G, Houssami N (2012) Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI. Breast 21: 669-677.
27. Mclaughlin R, Hylton N (2011) MRI in breast cancer therapy monitoring. NMR Biomed 24(6): 712-720.
28. Montemurro F, Martincich L, De Rosa G, Cirillo S, Marra V, Biglia N, Gatti M, Sismondi P, Aglietta M, Regge D (2005) Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. Eur Radiol 15(6): 1224-1233.
29. Moon HG, Han W, Lee JW, Ko E, Kim EK, Yu JH, Kang SY, Moon WK, Cho N, Park IA, Oh DY, Han SW, Im SA, Noh DY (2009) Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 20(4): 636-641.
30. Nakahara H, Yasuda Y, Machida E, Maeda Y, Furusawa H, Komaki K, Funagayama M, Nakahara M, Tamura S, Akiyama F (2010) MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: Comparison of triple negative breast cancer and other intrinsic subtypes. Breast Cancer 18(3): 152-160.
31. Padhani AR, Husband JE (2000) Are current tumour response criteria relevant for the 21st century? Br J Radiol 73(874): 1031-1033.
32. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM (2002) Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol 179(5): 1193-1199.
33. Prati R, Minami CA, Gornbein JA, Debruhl N, Chung D, Chang HR (2009) Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer 115(6): 1194-1202.
34. Pritt B, Tessitore JJ, Weaver DL, Blaszyk H (2005) The effect of tissue fixation and processing on breast cancer size. Hum Pathol 36(7): 756-760.
35. Pritt B, Weaver DL (2005) Accurate determination of breast cancer size: The role of histopathology and imaging. Curr Diagn Pathol 11(6): 435-442.
36. Provencher L, Diorio C, Hogue JC, Doyle C, Jacob S (2012) Does breast cancer tumor size really matter that much? Breast 21(5): 682-685.
37. Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, Samulski TV, Dewhirst MW (2003) Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol 181(5): 1275-1282.
38. Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, Helbich T, Heywang-Kobrunner SH, Kaiser WA, Kerin MJ, Mansel RE, Marotti L, Martincich L, Mauriac L, Meijers-Heijboer H, Orecchia R, Panizza P, Ponti A, Purushotham AD, Regitnig P, Del Turco MR, Thibault F, Wilson R (2010) Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group. Eur J Cancer 46(8): 1296-1316.
39. Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M (2007) Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96(6): 474-480.
40. Tucker FL (2012) Imaging-assisted large-format breast pathology: Program rationale and development in a nonprofit health system in the United States. Int J Breast Cancer 1(1): Http://www.hindawi.com/journals/ijbc/2012/171792/cta/.
41. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM (2001) MRI vs. histologic measurement of breast cancer following chemotherapy: Comparison with x-ray mammography and palpation. J Magn Reson Imaging 13(6): 868-875.
42. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J (2003) The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3: 1-13.
43. Whiting PF, Weswood ME, Rutjes AWS, Reitsma JB, Bossuyt PNM, Kleijnen J (2006) Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 6: 9.
44. Woodward M (1999) Basic analytical procedures. In Epidemiology: Study Design and Data Analysis. pp 31-105. Chapman & Hall/CRC: Boca Raton.
45. Wright FC, Zubovits J, Gardner S, Fitzgerald B, Clemons M, Quan ML, Causer P (2010) Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer - clinical examination, mammography, or magnetic resonance imaging? J Surg Oncol 101(7): 604-610.
46. Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, Halpern E, Moore R, Kuter I, Taghian A (2005) Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol 184(3): 868-877.